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The unique metabolism of most solid tumours (aerobic glycolysis, i.e., Warburg effect) is not only the basis of diagnosing cancer with
metabolic imaging but might also be associated with the resistance to apoptosis that characterises cancer. The glycolytic phenotype in
cancer appears to be the common denominator of diverse molecular abnormalities in cancer and may be associated with a
(potentially reversible) suppression of mitochondrial function. The generic drug dichloroacetate is an orally available small molecule
that, by inhibiting the pyruvate dehydrogenase kinase, increases the flux of pyruvate into the mitochondria, promoting glucose
oxidation over glycolysis. This reverses the suppressed mitochondrial apoptosis in cancer and results in suppression of tumour growth
in vitro and in vivo. Here, we review the scientific and clinical rationale supporting the rapid translation of this promising metabolic
modulator in early-phase cancer clinical trials.
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A PARADIGM SHIFT IS NEEDED IN CANCER
THERAPEUTICS
Although some battles have been won since the declaration of the
‘war on cancer’ in 1971 in the United States, the war is ongoing.
Despite enormous investments from industry and the public,
oncology has an impressively poor success rate in the clinical
development of effective investigational drugs; less than a third of
that in cardiovascular or infectious diseases (Kamb et al, 2007).
Drug development in oncology has typically focused on targets
essential for the survival of all dividing cells, leading to narrow
therapeutic windows. Non-essential targets offer more selectivity
but little efficacy. It is extremely rare to find an essential target that
is unique to cancer cells; the dependence of CML cells on Ableson
kinase is only induced by a chromosomal translocation in the
malignant clone, making the efficacy and selectivity of imatinib for
CML an exception in cancer therapy (Kamb et al, 2007). The most
important reason for the poor performance of cancer drugs is the
remarkable heterogeneity and adaptability of cancer cells. The
molecular characteristics of histologically identical cancers are
often dissimilar and molecular heterogeneity frequently exists
within a single tumour. The view that ‘there are many different
types of cancers’ is increasingly shared by scientists and clinical
oncologists. This has important implications, including the
realisation that specific drugs have to be developed and tested
for molecularly defined tumours and effects in one might not
necessarily be relevant to another cancer.
The biggest challenge remains the selective induction of cell
death (mainly apoptosis) in cancer but not normal cells. Pragma-
tically, an ideal anticancer therapy would be easily administered
(possibly an orally available small molecule) and affordable. Most
new anticancer drugs are prohibitively expensive not only for
millions of patients from developing countries, but also for many
patients without strong medical insurance in developed countries.
One way that the problem of heterogeneity of ‘proximal’
molecular pathways in cancer can be addressed is by targeting
more ‘distal’ pathways that integrate several proximal signals, as
long as the common distal pathways remain essential and specific
to cancer cells. The unique metabolism of most solid tumours
integrates many proximal pathways and results in a remodeling of
mitochondria (where the regulation of energy production and
apoptosis converge), to produce a glycolytic phenotype and a strong
resistance to apoptosis. There is now growing evidence that the
mitochondria might be primary targets in cancer therapeutics
instead of simple bystanders during cancer development. This
cancer-specific metabolic remodeling can be reversed by dichloro-
acetate (DCA), a mitochondria-targeting small molecule, that
penetrates most tissues after oral administration (Bonnet et al,
2007; Pan and Mak, 2007). The molecular and direct metabolic
response to DCA can also be followed by measuring glucose uptake
in tumours by positron emission tomography (PET) imaging, non-
invasively and prospectively. Such metabolic strategies might be
able to shift the paradigm of experimental therapeutics in oncology.
The preclinical work on DCA (showing effectiveness in a variety
of tumours and relatively low toxicity) (Bonnet et al, 2007), its
structure (a very small molecule), the low price (it is a generic
drug) and the fact that DCA has already been used in humans for
more than 30 years, provide a strong rationale for rapid clinical
translation. Here, we expand the scientific rationale and discuss
several practical points that will be important in the clinical
evaluation of DCA as anticancer therapy.
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Most cancers are characterised by aerobic glycolysis (GLY), that is,
they use glycolysis for energy production, despite the fact that
oxygen is present. In 1929, Warburg first observed this (i.e., the
Warburg effect) and suggested it resulted from mitochondrial
dysfunction, preventing the mitochondria-based glucose oxidation
(GO) (Warburg, 1930). Because GO is far more efficient in
generating ATP compared with GLY (producing 36 vs 2 ATP per
glucose molecule), cancer cells upregulate glucose receptors and
significantly increase glucose uptake in an attempt to ‘catch up’.
Positron emission tomography imaging has now confirmed that
most solid tumours have significantly increased glucose uptake
and metabolism, compared with non-cancerous tissues (Figure 1).
This bio-energetic difference between cancer and normal cells,
might offer a very selective therapeutic target, as GLY is not
typically seen in normal tissues apart from skeletal muscle during
strenuous exercise. However, this area of experimental oncology
has remained controversial; the glycolytic profile has traditionally
been viewed as a result of cancer progression, not a cause and
therefore the interest in targeting tumour metabolism has been
low. Furthermore, at first glance, the glycolytic profile of cancer is
difficult to understand, using an evolutionary model of carcino-
genesis. First, why would these highly proliferating and energy-
demanding cells rely on GLY rather than the much more efficient
GO? Second, GLY results in significant lactic acidosis, which might
cause significant toxicity to the surrounding tissues and the cancer
cells themselves. Recent advances have caused a rekindling of the
metabolic hypothesis of cancer suggesting that these facts are not
as conflicting as they appear at first (Gatenby and Gillies, 2004):
GLYCOLYSIS OFFERS AN EARLY ADAPTATION
TO THE HYPOXIC MICROENVIRONMENT IN
CARCINOGENESIS
Gatenby and Gillies (2004) recently proposed that as early carcino-
genesis often occurs in a hypoxic microenvironment, the trans-
formed cells have to rely on anaerobic GLY for energy production.
Hypoxia-inducible factor (HIF) is activated in hypoxic conditions
and it has been shown to induce the expression of several glucose
transporters and most of the enzymes required for GLY (Semenza
et al, 1994). For example, HIF induces the expression of pyruvate
dehydrogenase kinase (PDK) (Kim et al, 2006), a gate-keeping
enzyme that regulates the flux of carbohydrates (pyruvate) into the
mitochondria. In the presence of activated PDK, pyruvate
dehydrogenase (PDH) is inhibited, limiting the entry of pyruvate
into the mitochondria, where GO can take place. In other words,
activated PDK promotes completion of GLY in the cytoplasm with
metabolism of pyruvate into lactate; inhibited PDK ensures an
efficient coupling between GLY and GO.
Initially, tumours compensate by increasing glucose uptake into
the cells. Furthermore, Gatenby and Gillies (2004) list a number of
mechanisms through which lactic acidosis facilitates tumour
growth: breakdown of extra-cellular matrix allowing expansion,
increased cell mobility/metastatic potential and (along with HIF)
activation of angiogenesis. Although tumours eventually become
vascularised and are not significantly hypoxic anymore (although
some tumours remain hypoxic at the core because the quality of
the neo-vessel formation is poor) the aerobic glycolytic profile
persists. This suggests that the (initially adaptive) metabolic
remodeling confers a survival advantage to cancer cells. Indeed,
recent evidence suggests that transformation to a glycolytic
phenotype offers resistance to apoptosis (Plas and Thompson,
2002) (Kim and Dang, 2005, 2006).
GLYCOLYSIS IS ASSOCIATED WITH RESISTANCE
TO APOPTOSIS
Several of the enzymes involved in glycolysis are also important
regulators of apoptosis and gene transcription, suggesting that
links between metabolic sensors, cell death and gene transcription
are established directly through the enzymes that control
metabolism (Kim and Dang, 2005). For example, hexokinase
activation leads to a significant suppression of apoptosis; activated
hexokinase translocates from the cytoplasm to the mitochondrial
membranes where it interacts with and suppresses several key
components of mitochondria-dependent apoptosis (Pastorino
et al, 2005). It is therefore not surprising that hexokinase is
upregulated and activated in many cancers (Kim and Dang, 2006).
How does this occur? The promoter of hexokinase contains both
p53 and HIF response elements and both mutated p53 and
activated HIF increase hexokinase expression (Mathupala et al,
1997). In addition, the oncogenic protein Akt is upregulated in
many cancers and induces a glycolytic metabolic profile through a
number of mechanisms (Elstrom et al, 2004). Akt increases both
the expression and activity of hexokinase (Gottlob et al, 2001;
Elstrom et al, 2004). The gene that normally antagonises Akt,
PTEN, is mutated (loss of function mutation) in a large number of
cancers. Very recent data revealed even more links between p53
and metabolism: p53 regulates the expression of a critical enzyme
of GLY through the production of TIGAR and is also directly
regulating the expression of a subunit of cytochrome c oxidase,a n
important element of complex IV of the electron transport chain in
mitochondria (reviewed in (Pan and Mak, 2007)). In other words,
the most common molecular abnormality in cancer, that is, the
loss of p53 function, induces metabolic and mitochondrial
changes, compatible with the glycolytic phenotype. Likewise, the
c-myc transcription factor increases the expression of many
enzymes of GLY and can induce this same metabolic phenotype
(Kim and Dang, 2005, 2006).
To conclude, an evolutionary theory of carcinogenesis identifies
metabolism and GLY as a critical and early adaptive mechanism
of cancer cells against hypoxia, that persist because it offers
resistance to apoptosis in cancer cells (Gatenby and Gillies, 2004).
The genetic theory on carcinogenesis, also identifies GLY and
metabolism as an end result of activation of many diverse
oncogenes, including c-myc, Akt/PTEN and p53 (Pan and Mak,
2007). Therefore, it is possible that this metabolic phenotype is
centrally involved in the pathogenesis of cancer and is not simply a
‘by-product’ of carcinogenesis. Although it is not clear whether
MRI PET
Figure 1 Brain MRI showing a large glioblastoma tumour with areas of
necrosis within the tumour and significant brain oedema. On the right, a
corresponding FDG-Glucose PET from the same patient shows much
higher glucose uptake within the tumour, compared with the surrounding
brain tissue.
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‘facilitates’ carcinogenesis (Kim and Dang, 2006). In addition, this
metabolic signature is the common denominator of multiple and
diverse pathways; which means that if it is therapeutically targeted
it might offer selectivity for malignant cells of diverse cellular and
molecular origins.
MITOCHONDRIA AND APOPTOSIS
Shifting metabolism away from mitochondria (GO) and towards
the cytoplasm (GLY), might suppress apoptosis, a form of cell
death that is dependent on mitochondrial energy production
(Figure 2). Pro-apoptotic mediators, like cytochrome c and
apoptosis-inducing factor, are protected inside the mitochondria.
When the voltage- and redox-sensitive mitochondrial transition
pore (MTP) opens, they are released in the cytoplasm and induce
apoptosis, although it is possible that this can occur without MTP
opening (Halestrap, 2005). Mitochondrial depolarisation and
increased ROS are associated with opening of the MTP (Zamzami
and Kroemer, 2001). Mitochondrial membrane potential and ROS
production are dependent on the flux of electrons down the
electron transport chain (ETC), which in turn are dependent on the
production of electron donors (NADH, FADH2) from the Krebs’
cycle. Suppressing the entry of pyruvate into the mitochondria and
thus the production of acetyl-CoA, will suppress both Krebs’ cycle
and the ETC and thus MTP opening and apoptosis.
Mitochondria can also affect downstream mechanisms involved
in proliferation and apoptosis. For example, mitochondria uptake
can directly regulate intracellular Ca
þþ, the increase of which
is associated with increased proliferation and activation of many
transcription factors. Also, the mitochondria-produced superoxide
can be dismutated to H2O2 through the manganese superoxide
dismutase and diffuse freely, activating plasma membrane K
þ
channels, thereby regulating the influx of Ca
þþand the activity of
caspases. K
þ channels are transmembrane proteins allowing the
passage of K
þ ions through the plasma membrane. Closing of K
þ
channels or decreasing their expression results in an increase in
[K
þ]i which, in turn, increases the tonic inhibition that cytosolic
K
þ exerts on caspases (Remillard and Yuan, 2004). The voltage-
gated family of K
þ channels (Kv) is redox-sensitive and therefore
can be regulated by the mitochondria. For example, mitochondria-
derived H2O2 can activate certain Kv channels, like Kv1.5 (Bonnet
et al, 2007).
DCA REVERSES THE MITOCHONDRIAL
REMODELING, UNLOCKING THE CANCER CELLS
FROM A STATE OF APOPTOSIS RESISTANCE:
PRECLINICAL WORK
We recently showed that several cancer cell lines (non-small cell
lung cancer, breast cancer and glioblastoma) had hyperpolarised
mitochondria, compared with non-cancer cell lines (Bonnet et al,
2007), a finding that was first described by Dr Chen at the Dana
Farber Institute in the 1980s (Chen, 1988). This was associated with
suppressed levels of mitochondria-derived ROS and decreased
activity and expression of Kv channels. The Ca
þþ-sensitive
transcription factor NFAT was also active (i.e., nuclear) in the
cancer cells. NFAT is a transcription factor that has been shown to
increase the levels of the antiapoptotic bcl-2 and decrease the levels
of the Kv channel Kv1.5. All of these features are compatible with
an antiapoptotic state and could be secondary to a suppressed
mitochondrial activity: decrease entry of pyruvate would even-
tually result in decrease flux of electrons in the ETC and therefore
decreased ROS production, closing of the existing redox-sensitive
Kv channels and increased intracellular Ca
þþ. The decreased ROS
could also contribute to closure of the redox-sensitive MTP and
mitochondrial hyperpolarisation. The decreased entry of pyruvate
into the mitochondria (and therefore the decreased GO) would
result in compensatory GLY. Increased hexokinase levels would
contribute to the hyperpolarisation of the mitochondria; increased
hexokinase in a glycolytic environment is known to
be translocated to the mitochondrial membrane, inhibiting the
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Figure 2 A glycolytic environment is associated with an antiapoptotic and pro-proliferative state, characterizing most solid tumours. Increase entry of
pyruvate into the mitochondria by either DCA or inhibition of LDH, promotes glucose oxidation, increased apoptosis and decreased proliferation and
tumour growth (see text for discussion).
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resulting in hyperpolarisation and suppression of apoptosis
(Pastorino et al, 2005) (Figure 2).
Dichloroacetate activated the pyruvate dehydrogenase, which
resulted in increased delivery of pyruvate into the mitochondria.
As predicted, DCA increased GO and depolarised the mitochon-
dria, returning the membrane potential towards the levels of the
non-cancer cells, without affecting the mitochondria of non-
cancerous cells (Figure 2). Remarkably, all the above features of
the cancer cells were ‘normalised’ following the increase in GO and
the mitochondrial depolarisation: ROS increased, NFAT was
inactivated and function/expression of Kv channels was increased.
Most importantly, apoptosis was induced in the cancer cells with
both cytochrome c and apoptosis-inducing factor efflux from the
mitochondria. This resulted in a decrease in tumour growth both
in vitro and in vivo in xenotransplant models (Bonnet et al, 2007)
(Figure 3). In addition to the induction of apoptosis by DCA in
non-small cell lung cancer, breast cancer and glioblastoma cell
lines reported in our original publication (Bonnet et al, 2007), very
recently DCA was shown to induce apoptosis in endometrial
(Wong et al, 2008) and prostate (Cao et al, 2008) cancer cells by
largely the same mechanism, independently confirming our
results. Furthemore, as predicted, activating mitochondria by
DCA increases O2 consumption in the tumour and dramatically
enhances the effectiveness of hypoxia-specific chemotherapies in
animal models (Cairns et al, 2007).
It is important here to clarify that simply inhibiting GLY, will
not promote pyruvate entry into the mitochondria, that is, it will
not re-activate mitochondria. It will also be toxic to several non-
cancerous tissues that depend on GLY for energy production.
Inhibiting GLY (which has previously been tested as a potential
treatment for cancer) results in ATP depletion and necrosis, not
apoptosis, because apoptosis is an energy-consuming process,
requiring active mitochondria (Xu et al, 2005). The ‘trick’ is to
enhance the GLY to GO coupling, not just inhibit GLY. One of the
ways that this can happen is by activating PDH, or inhibiting LDH,
bringing pyruvate into the mitochondria and enhancing GO
(Figure 2). This hypothesis is also supported by the recently
published work that inhibition of LDH (by siRNA), which
promotes the transfer of pyruvate into the mitochondria (in that
sense mimicking DCA), also promotes cancer apoptosis and
decreases tumour growth in vitro and in mice xenotransplants
(Fantin et al, 2006).
DCA: MECHANISM OF ACTION AND CLINICAL
EXPERIENCE
Dichloroacetate is a small molecule of 150Da (see structure in
Figure 3) explaining in part the high bioavailability of this drug
and the fact that it can penetrate into the traditional chemotherapy
sanctuary sites, including the brain. In vitro, DCA activates PDH
by inhibition of PDK at concentration of 10–250mM or 0.15–
37.5mgml
 1 in a dose-dependent fashion (Stacpoole, 1989). To
date, four different isoforms of PDK have been identified that have
variable expression and sensitivity to the inhibition by DCA
(Sugden and Holness, 2003). The isozyme constitutively expressed
in most tissues and with the highest sensitivity to DCA is PDKII; in
our published preclinical work we showed that PDK2 inhibition
with siRNA completely mimicked DCA effects (Bonnet et al, 2007).
Oral DCA can achieve 100% bioavailability. Many studies using
IV and oral DCA aimed to identify the optimal dose for DCA. The
end point measured was the decrease in lactate levels in both the
blood and the cerebrospinal fluid. A decrease in lactate levels is the
immediate result of the inhibition of PDK (and thus activation of
PDH) by DCA. Several studies treated patients with DCA and
directly measured PDH activity in muscle biopsies. Dichloroace-
tate administered at 35–50mgkg
 1 decreases lactate levels by
more than 60% and directly activates PDH by 3–6 fold (Howlett
et al, 1999; Parolin et al, 2000).
Although the pharmacokinetics of DCA in healthy volunteers
follow a simple one-compartment model, they are more complex
in severely abnormal states like severe lactic acidosis or cirrhosis.
Dichloroacetate inhibits its own metabolism by an unknown
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Figure 3 Dichloroacetate depolarises mitochondria and suppresses tumour growth in vivo. On the left, non-small cell lung cancer cells are loaded with
TMRM before and after treatment with DCA (the higher the red fluorescence the higher the mitochondrial membrane potential; nuclei in blue). The same
cells were injected in the flank of nude rats. On the right these rats are imaged with a rodent PET-CT (GammaMedica). Simultaneous CT and FDG-Glucose
PET imaging shows that DCA therapy decreases both the size and the glucose uptake in the tumour.
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multiple doses (Stacpoole et al, 2003). Although the initial
half-life with the first dose is less than one hour, this half-life
increases to several hours with subsequent doses. However,
there is a plateau of this effect and DCA serum levels do not
continue to rise with chronic use. This is also true for DCA
metabolites (which do not have any biologic effect, at least on
PDH). For example, the serum DCA levels after 5 years of
continued treatment with oral DCA at 25mgkg
 1 are only slightly
increased compared with the levels after the first several doses
(and remain in the range of approximately 100mgml
 1) (Mori
et al, 2004). The effects on lactate levels are sustained and persist
after the DCA levels decrease, because the inhibition of PDK is not
immediately reversible; DCA ‘locks’ PDK in a sustained inactive
state.
A large number of children and adults have been exposed
to DCA over the past 40 years, including healthy volunteers
and subjects with diverse disease states. Since its first description
in 1969 (Stacpoole, 1969), DCA has been studied to alleviate
the symptoms or the haemodynamic consequences of the
lactic acidosis complicating severe malaria, sepsis, congestive
heart failure, burns, cirrhosis, liver transplantation and
congenital mitochondrial diseases. Single-arm and randomised
trials of DCA used doses ranging from 12.5 to 100mgkg
 1day
 1
orally or intravenously (reviewed in (Stacpoole et al,
2003)). Although DCA was universally effective in lowering lactate
levels, it did not alter the course of the primary disease (for
example sepsis).
More than 40 nonrandomised trials of DCA in small cohorts
of patients have been reported, but the first two randomised
control trials of chronic oral therapy with DCA in congenital
mitochondrial diseases were reported in 2006. In the first,
a blinded placebo-controlled study was performed with oral
DCA administered at 25mgkg
 1day
 1 in 30 patients with MELAS
syndrome (mitochondrial myopathy, encephalopathy, lactic acido-
sis and stroke-like episodes) (Kaufmann et al, 2006). Most
patients enrolled in the DCA arm developed symptomatic
peripheral neuropathy, compared with 4 out of 15 in the
placebo arm, leading to the termination of the study. Seventeen
out of 19 patients had at least partial resolution of peripheral
neurological symptoms by 9 months after discontinuation of DCA.
This neurotoxicity resembled the pattern of length-dependent,
axonal, sensorimotor polyneuropathy without demyelination. No
other toxicities were reported. It is important to note that
peripheral neuropathy often complicates MELAS because of
primary or secondary effects on peripheral nerves; for example
these patients also have diabetes and diabetes-related peripheral
neuropathy.
In contrast, another randomised placebo-controlled double-
blinded study failed to show any significant toxicity of DCA,
including peripheral neuropathy. In this study only one of
21 children with congenital lactic acidosis treated with DCA orally
at 25mgkg
 1day
 1 for 6 months demonstrated mild peripheral
neuropathy. Serial nerve conduction studies failed to demonstrate
any difference in incidence of neuropathy in the 2 arms (placebo vs
DCA). Sleepiness and lethargy, muscular rigidity of the upper
extremity and hand tremor were reported in one patient in each
group (Stacpoole et al, 2006).
The higher incidence of peripheral neuropathy in adult MELAS
patients may represent an intrinsic predisposition to this
complication in MELAS or its associated conditions, that is,
diabetes mellitus; this toxicity might also be age-dependent. In
summary, peripheral neuropathy is a potential side effect of DCA
that appears to be largely reversible. As peripheral neuropathy is a
frequent complication of taxane, platinum and vinca-alkaloid
chemotherapies, the risk for DCA-associated peripheral neuro-
pathy may depend on whether cancer patients have prior or
concurrent neurotoxic therapy.
DCA: CLINICAL TESTING IN CANCER?
There is substantial evidence in preclinical in vitro and in vivo
models that DCA might be beneficial in human cancer (Bonnet
et al, 2007; Cairns et al, 2007; Cao et al, 2008; Wong et al, 2008).
The concept is strengthened by the fact that LDH inhibition in
mice with human cancer xenotransplants, also induced apoptosis
and inhibited growth, improving survival (Fantin et al, 2006).
There is also 40 years of human experience with mechanistic
studies of DCA in human tissues after oral use, pharmacokinetic
and toxicity data from randomised studies for 6 months, and
5-year use case reports. This supports an easy translation to early-
phase clinical trials.
Dichloroacetate could be tested in a variety of cancer types. The
realisation that (i) a diverse group of signalling pathways and
oncogenes result in resistance to apoptosis and a glycolytic
phenotype, (ii) the majority of carcinomas have hyperpolarised/
remodeled mitochondria, and (iii) most solid tumours have
increased glucose uptake on PET imaging, suggest that DCA
might be effective in a large number of diverse tumours. However,
direct preclinical evidence of anticancer effects of DCA has been
published only with non-small cell lung cancer, glioblastoma and
breast, endometrial and prostate cancer. In addition, the lack of
mitochondrial hyperpolarisation in certain types of cancer,
including oat cell lung cancer, lymphomas, neuroblastomas and
sarcomas (Chen, 1988), suggest that DCA might not be effective in
such cases. Cancers with limited or no meaningful therapeutic
options like recurrent glioblastoma or advanced lung cancer
should be on top of the list of cancers to be studied.
No patient with cancer has received DCA within a clinical trial.
It is unknown whether previously studied dose ranges will achieve
cytotoxic intra-tumoral concentrations of DCA. In addition,
the overall nutritional and metabolic profile of patients with
advanced cancer differs from those in the published DCA studies.
Furthermore, pre-exposure to neurotoxic chemotherapy may
predispose to DCA neurotoxicity. Carefully performed phase I
dose escalation and phase II trials with serial tissue biopsies are
required to define the maximally tolerated, and biologically active
dose. Clinical trials with DCA will need to carefully monitor
neurotoxicity and establish clear dose-reduction strategies to
manage toxicities. Furthermore, the pharmacokinetics in the
cancer population will need to be defined.
The preclinical experience with DCA monotherapy warrants
clinical trials with DCA as a single agent or in direct comparison
with other agents. However, as it ‘unlocks’ cancer cells from a state
of apoptosis resistance, DCA might be an attractive ‘apoptosis-
sensitizer’ agent. In that sense, DCA could both precede and be
given concurrently with chemotherapy or radiation therapy, in an
attempt to increase their effectiveness, decrease the required doses
and limit the toxicity of standard therapies (Cairns et al, 2007).
The ability to approach metabolism as an integrator of many
diverse signalling pathways, prompts consideration of the imaging
and diagnostic studies that might track metabolic modulation. As
discussed above, important questions that need to be answered in
clinical trials using DCA include: (i) can PET be used as a predictor
of clinical response or as a means of documenting non-invasively a
reversal of the glycolytic phenotype in response to DCA? (ii) can
mitochondrial membrane potential or the acute effects on DCA in
fresh tumour biopsies, predict clinical response to DCA and
facilitate patient selection?
Funding for such trials would be a challenge for the academic
community as DCA is a generic drug and early industry support
might be limited. Fundraising from philanthropies might be
possible to support early phase I–II or small phase III trials.
However, if these trials suggest a favourable efficacy and toxicity,
the public will be further motivated to directly fund these efforts
and national cancer organisations like the NCI, might be inspired
to directly contribute to the design and structure of larger trials.
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‘dawn of a new era’ (Pan and Mak, 2007), initiation and completion
of clinical trials with a generic compound will be a task of
tremendous symbolic and practical significance. At this point the
‘dogma’ that trials of systemic anticancer therapy cannot happen
without industry support, suppresses the potential of many
promising drugs that might not be financially attractive for
pharmaceutical manufacturers. In that sense, the clinical evalua-
tion of DCA, in addition to its scientific rationale, will be by itself
another paradigm shift.
NOTE TO PROOF
Since the acceptance of this review two important papers have
confirmed the novel anticancer effects of DCA in prostate and
endometrial cancers: Wong JY et al, Dichloroacetate induces
apoptosis in endometrial cancer cells. Gynecol Oncol June
2008; 109(3): 394–402 and Gao et al, Dichloroacetate (DCA)
sensitizes both wild-type and over expressing Bcl-2 prostate
cancer cells in vitro to radiation. Prostate 1 August 2008; 68(11):
1223–1231.
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